<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048061</url>
  </required_header>
  <id_info>
    <org_study_id>BM16549</org_study_id>
    <nct_id>NCT00048061</nct_id>
  </id_info>
  <brief_title>MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis</brief_title>
  <official_title>Randomized, Double-blind, Double Dummy, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of Monthly Oral Administration of 100 mg and 150 mg Ibandronate With 2.5 mg Daily Oral Ibandronate in Postmenopausal Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will compare the efficacy and safety of different treatment regimens of oral
      Bonviva tablets in women with post-menopausal osteoporosis. Patients will also receive daily
      supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+
      years, and the target sample size is 500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 - L4) Bone Mineral Density</measure>
    <time_frame>From Baseline (Month 0) to Month 12</time_frame>
    <description>Relative change in Bone Mineral Density (BMD) is the percentage change from baseline of BMD of vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center after 12 months of treatment. It is calculated as the sum of bone mineral content divided by the sum of area of all lumbar vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process at Month 12. Participants available at particular time point for assessment were included in the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline at Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD</measure>
    <time_frame>From Baseline (Month 0) to Month 24</time_frame>
    <description>Relative change in BMD is the percentage change from baseline of BMD of vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center after 24 months of treatment. It is calculated as the sum of bone mineral content divided by the sum of area of all lumbar vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process at Month 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD</measure>
    <time_frame>From Baseline (Month 0) to Months 12 and 24</time_frame>
    <description>The absolute change (g/cm^2) from baseline in mean BMD of the lumbar spine (L2 - L4) at one and two years. A difference in the mean values between the active groups and the control was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD</measure>
    <time_frame>From Baseline (Month 0) to Months 12 and 24</time_frame>
    <description>Proximal femur BMD was measured by dual-energy X ray absorptiometry at baseline, after one and two years of treatment and was read by a central reading center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD.</measure>
    <time_frame>From Baseline (Month 0) to Months 12 and 24</time_frame>
    <description>Proximal femur BMD was measured by dual-energy X-ray absorptiometry at baseline, after one and two years of treatment and was read by a central reading center</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Lumbar Spine (L2 - L4) BMD Above or Equal to Baseline at Months 12 and 24</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>A participant is a responder if the mean lumber spine (L2 - L4) BMD had remained the same or increased above baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Months 12 and 24</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>A participant is a responder if the mean total hip BMD had remained the same or increased above baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Months 12 and 24</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>A participant is a responder if the mean trochanter BMD had remained the same or increased above baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Months 12 and 24</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>A participant is a responder if the mean femoral neck BMD had remained the same or increased above baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>A participant is a responder if the mean total hip and mean lumbar spine BMD had remained the same or increased above baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>A participant is a responder if the mean trochanter and lumbar spine BMD had remained the same or increased above baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>A participant is a responder if the mean femoral neck and lumbar spine BMD had remained the same or increased above baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change In Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen [ CTX] ] to Months 3, 6, 12, and 24</measure>
    <time_frame>From Baseline (Month 0) to Months 3, 6, 12, 24</time_frame>
    <description>Serum CTX, a biochemical marker of bone resorption, was assessed using the Elecsys S-CTX-I assay (an ElectroChemiLuminescence Immunoassay (ECLIA) Technique).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change In Baseline in Serum CTX to Months 12 and 24</measure>
    <time_frame>From Baseline (Month 0) to Months 12 and 24</time_frame>
    <description>Serum CTX, a biochemical marker of bone resorption, was assessed using the Elecsys S-CTX-I assay (an ElectroChemiLuminescence Immunoassay (ECLIA) Technique).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Events and Serious Adverse Event</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants With Marked Laboratory Abnormalities</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from baseline. The reference range for hemoglobin was 110-200 (gram per liter [g/L]), hematocrit was 0.31-0.56 fraction, white blood cells (WBC) was 3.0-18.0 (10*9/L), serum glutamic-pyruvic transaminase (SGPT/ALT) was 0-110 IU/L, blood urea nitrogen (BUN) was 0.0-14.3 (millimoles per Liter [mmol/L]), Chloride was 95-115 (mmol/L), Potassium was 3.0 - 6.0 (mmol/L), Sodium was 130-150 (mmol/L), Calcium was 2.00-2.90 (mmol/L), Phosphate was 0.75 - 1.60 (mmol/L) and Creatinine was 0- 154 (micromoles/liter [umol/L].</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1609</enrollment>
  <condition>Post Menopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Ibandronate 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibandronate 50/50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibandronate 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibandronate 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate [Bonviva/Boniva]</intervention_name>
    <description>2.5mg po daily</description>
    <arm_group_label>Ibandronate 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate [Bonviva/Boniva]</intervention_name>
    <description>100mg po monthly on a single day</description>
    <arm_group_label>Ibandronate 50/50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate [Bonviva/Boniva]</intervention_name>
    <description>100mg po monthly over 2 consecutive days</description>
    <arm_group_label>Ibandronate 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate [Bonviva/Boniva]</intervention_name>
    <description>150mg po monthly</description>
    <arm_group_label>Ibandronate 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>500 mg/day</description>
    <arm_group_label>Ibandronate 2.5 mg</arm_group_label>
    <arm_group_label>Ibandronate 50/50 mg</arm_group_label>
    <arm_group_label>Ibandronate 100 mg</arm_group_label>
    <arm_group_label>Ibandronate 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>400 IU/day</description>
    <arm_group_label>Ibandronate 2.5 mg</arm_group_label>
    <arm_group_label>Ibandronate 50/50 mg</arm_group_label>
    <arm_group_label>Ibandronate 100 mg</arm_group_label>
    <arm_group_label>Ibandronate 150 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women 55-80 years of age;

          -  post-menopausal for &gt;= 5 years;

          -  ambulatory.

        Exclusion Criteria:

          -  malignant disease diagnosed within the previous 10 years (except basal cell cancer
             that has been successfully removed);

          -  breast cancer within the previous 20 years;

          -  allergy to bisphosphonates;

          -  previous treatment with an intravenous bisphosphonate at any time;

          -  previous treatment with an oral bisphosphonate within the last 6 months, &gt;1 month of
             treatment within the last year, or &gt;3 months of treatment within the last 2 years.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <zip>6979</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <zip>13077-005</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <zip>80060-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04026-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>169 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfuered</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiskunhalas</city>
        <zip>6400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valeggio Sul Mincio</city>
        <zip>37067</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obregon</city>
        <zip>85100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haugesund</city>
        <zip>5507</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0176</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavanger</city>
        <zip>4010</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <zip>CF64 2XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2002</study_first_submitted>
  <study_first_submitted_qc>October 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2002</study_first_posted>
  <results_first_submitted>February 5, 2016</results_first_submitted>
  <results_first_submitted_qc>April 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2016</results_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted from 26 April 2002 to 08 Dec 2004 across 65 centers in the world.</recruitment_details>
      <pre_assignment_details>A total of 1609 participants were randomized, of which 1602 received the study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibandronate 2.5 mg</title>
          <description>Participants received 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 international units (IU) per day.</description>
        </group>
        <group group_id="P2">
          <title>Ibandronate 50/50 mg</title>
          <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
        <group group_id="P3">
          <title>Ibandronate 100 mg</title>
          <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
        <group group_id="P4">
          <title>Ibandronate 150 mg</title>
          <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
                <participants group_id="P2" count="401"/>
                <participants group_id="P3" count="400"/>
                <participants group_id="P4" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="325"/>
                <participants group_id="P2" count="328"/>
                <participants group_id="P3" count="316"/>
                <participants group_id="P4" count="322"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early improvement</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population consisted of all participants who were randomized and received at least one dose of the study medication, and who have at least one follow-up data point.</population>
      <group_list>
        <group group_id="B1">
          <title>Ibandronate 2.5 mg</title>
          <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
        <group group_id="B2">
          <title>Ibandronate 50/50 mg</title>
          <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
        <group group_id="B3">
          <title>Ibandronate 100 mg</title>
          <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
        <group group_id="B4">
          <title>Ibandronate 150 mg</title>
          <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="395"/>
            <count group_id="B2" value="396"/>
            <count group_id="B3" value="396"/>
            <count group_id="B4" value="396"/>
            <count group_id="B5" value="1583"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="6.61"/>
                    <measurement group_id="B2" value="66.0" spread="6.71"/>
                    <measurement group_id="B3" value="66.2" spread="6.38"/>
                    <measurement group_id="B4" value="66.2" spread="6.64"/>
                    <measurement group_id="B5" value="66.0" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="395"/>
                    <measurement group_id="B2" value="396"/>
                    <measurement group_id="B3" value="396"/>
                    <measurement group_id="B4" value="396"/>
                    <measurement group_id="B5" value="1583"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 – L4) Bone Mineral Density</title>
        <description>Relative change in Bone Mineral Density (BMD) is the percentage change from baseline of BMD of vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center after 12 months of treatment. It is calculated as the sum of bone mineral content divided by the sum of area of all lumbar vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process at Month 12. Participants available at particular time point for assessment were included in the analysis.</description>
        <time_frame>From Baseline (Month 0) to Month 12</time_frame>
        <population>The per-protocol(PP) population included participants in Intent-to-treat(ITT) population who were randomized, received at least one dose of medication and had at least one valid efficacy(BMD or Serum CTX)follow-up data point;defined as any measurement that can be scientifically compared to baseline measurement, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 – L4) Bone Mineral Density</title>
          <description>Relative change in Bone Mineral Density (BMD) is the percentage change from baseline of BMD of vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center after 12 months of treatment. It is calculated as the sum of bone mineral content divided by the sum of area of all lumbar vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process at Month 12. Participants available at particular time point for assessment were included in the analysis.</description>
          <population>The per-protocol(PP) population included participants in Intent-to-treat(ITT) population who were randomized, received at least one dose of medication and had at least one valid efficacy(BMD or Serum CTX)follow-up data point;defined as any measurement that can be scientifically compared to baseline measurement, and had no major protocol violations.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7427" spread="4.0149"/>
                    <measurement group_id="O2" value="4.3395" spread="3.9557"/>
                    <measurement group_id="O3" value="4.0328" spread="3.6815"/>
                    <measurement group_id="O4" value="4.7611" spread="3.8931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The monthly dosing regimen (Ibandronate 50/50 mg monthly) was considered non-inferior to the 2.5 mg daily regimen if the lower bound of the two-sided 95% CI on the difference in mean percent change in BMD was greater or equal to –1 percentage point.</non_inferiority_desc>
            <p_value>0.045</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.615</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>1.216</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in the mean values of the monthly oral dose regimens (Ibandronate 50/50) and the active-control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The monthly dosing regimen (Ibandronate 100 mg) was considered non-inferior to the 2.5 mg daily regimen if the lower bound of the two-sided 95% CI on the difference in mean percent change in BMD was greater or equal to –1 percentage point.</non_inferiority_desc>
            <p_value>0.338</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.297</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.312</ci_lower_limit>
            <ci_upper_limit>0.906</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in the mean values of the monthly oral dose regimens (Ibandronate 100 mg) and the active-control</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The monthly dosing regimen (Ibandronate 150 mg) was considered non-inferior to the 2.5 mg daily regimen if the lower bound of the two-sided 95% CI on the difference in mean percent change in BMD was greater or equal to –1 percentage point.</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.395</ci_lower_limit>
            <ci_upper_limit>1.605</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in the mean values of the monthly oral dose regimens (Ibandronate 150 mg) and the active-control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline at Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD</title>
        <description>Relative change in BMD is the percentage change from baseline of BMD of vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center after 24 months of treatment. It is calculated as the sum of bone mineral content divided by the sum of area of all lumbar vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process at Month 24.</description>
        <time_frame>From Baseline (Month 0) to Month 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol.Participants available at particular time point for assessment were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline at Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD</title>
          <description>Relative change in BMD is the percentage change from baseline of BMD of vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process to such a degree that accurate measurement of BMD would be considered jeopardized by the central reading center after 24 months of treatment. It is calculated as the sum of bone mineral content divided by the sum of area of all lumbar vertebrae L2 - L4 that are not fractured and not affected by an osteoarthritic process at Month 24.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol.Participants available at particular time point for assessment were included in the analysis.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="294"/>
                <count group_id="O3" value="278"/>
                <count group_id="O4" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9623" spread="4.6525"/>
                    <measurement group_id="O2" value="5.3350" spread="4.8235"/>
                    <measurement group_id="O3" value="5.5760" spread="4.2280"/>
                    <measurement group_id="O4" value="6.5503" spread="4.5118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD</title>
        <description>The absolute change (g/cm^2) from baseline in mean BMD of the lumbar spine (L2 – L4) at one and two years. A difference in the mean values between the active groups and the control was calculated.</description>
        <time_frame>From Baseline (Month 0) to Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Lumbar Spine (L2-L4) BMD</title>
          <description>The absolute change (g/cm^2) from baseline in mean BMD of the lumbar spine (L2 – L4) at one and two years. A difference in the mean values between the active groups and the control was calculated.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 12 months, n = 314, 322, 306, 314</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" spread="0.0291"/>
                    <measurement group_id="O2" value="0.033" spread="0.0298"/>
                    <measurement group_id="O3" value="0.030" spread="0.0271"/>
                    <measurement group_id="O4" value="0.036" spread="0.0290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 24 months, n = 294, 294, 278, 291</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.0337"/>
                    <measurement group_id="O2" value="0.039" spread="0.0355"/>
                    <measurement group_id="O3" value="0.042" spread="0.0313"/>
                    <measurement group_id="O4" value="0.049" spread="0.0330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD</title>
        <description>Proximal femur BMD was measured by dual-energy X ray absorptiometry at baseline, after one and two years of treatment and was read by a central reading center.</description>
        <time_frame>From Baseline (Month 0) to Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD</title>
          <description>Proximal femur BMD was measured by dual-energy X ray absorptiometry at baseline, after one and two years of treatment and was read by a central reading center.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total hip At Month 12, n = 315,319,306,316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9626" spread="2.8311"/>
                    <measurement group_id="O2" value="2.2172" spread="2.7504"/>
                    <measurement group_id="O3" value="2.6878" spread="2.6646"/>
                    <measurement group_id="O4" value="3.0092" spread="2.7105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total hip At Month 24, n = 292,291,277,289</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4955" spread="3.0884"/>
                    <measurement group_id="O2" value="2.8132" spread="3.2408"/>
                    <measurement group_id="O3" value="3.5165" spread="3.2831"/>
                    <measurement group_id="O4" value="4.1601" spread="2.8335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter At Month 12, n = 315,319,306,316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1917" spread="4.1268"/>
                    <measurement group_id="O2" value="3.4931" spread="4.0876"/>
                    <measurement group_id="O3" value="3.8226" spread="3.7077"/>
                    <measurement group_id="O4" value="4.5904" spread="3.9436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter At Month 24, n = 292,291,277,289</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0204" spread="4.3460"/>
                    <measurement group_id="O2" value="4.6289" spread="4.5518"/>
                    <measurement group_id="O3" value="5.3135" spread="4.7335"/>
                    <measurement group_id="O4" value="6.1755" spread="4.2550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck At Month 12, n = 315,319,306,316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7164" spread="3.6233"/>
                    <measurement group_id="O2" value="1.8141" spread="3.4391"/>
                    <measurement group_id="O3" value="1.8797" spread="3.4998"/>
                    <measurement group_id="O4" value="2.1914" spread="3.4842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck At Month 24, n=292,291,277,289</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9087" spread="4.2212"/>
                    <measurement group_id="O2" value="2.0581" spread="4.1189"/>
                    <measurement group_id="O3" value="2.6209" spread="3.8339"/>
                    <measurement group_id="O4" value="3.1195" spread="4.0549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD.</title>
        <description>Proximal femur BMD was measured by dual-energy X-ray absorptiometry at baseline, after one and two years of treatment and was read by a central reading center</description>
        <time_frame>From Baseline (Month 0) to Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline at One Year (12 Months) and Two Years (24 Months) in Mean Proximal Femur ( Total Hip, Trochanter, Femoral Neck) BMD.</title>
          <description>Proximal femur BMD was measured by dual-energy X-ray absorptiometry at baseline, after one and two years of treatment and was read by a central reading center</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total hip At Month 12, n = 315,319,306,316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" spread="0.0204"/>
                    <measurement group_id="O2" value="0.016" spread="0.0205"/>
                    <measurement group_id="O3" value="0.020" spread="0.0190"/>
                    <measurement group_id="O4" value="0.022" spread="0.0190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total hip At Month 24, n = 292,291,277,290</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.0225"/>
                    <measurement group_id="O2" value="0.021" spread="0.0241"/>
                    <measurement group_id="O3" value="0.026" spread="0.0237"/>
                    <measurement group_id="O4" value="0.031" spread="0.0199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter At Month 12, n = 315,319,306,316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.0228"/>
                    <measurement group_id="O2" value="0.020" spread="0.0238"/>
                    <measurement group_id="O3" value="0.022" spread="0.0206"/>
                    <measurement group_id="O4" value="0.026" spread="0.0211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter At Month 24, n = 292,291,277,290</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.0241"/>
                    <measurement group_id="O2" value="0.027" spread="0.0259"/>
                    <measurement group_id="O3" value="0.030" spread="0.0263"/>
                    <measurement group_id="O4" value="0.035" spread="0.0231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck At Month 12, n = 315,319,306,316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.0230"/>
                    <measurement group_id="O2" value="0.011" spread="0.0226"/>
                    <measurement group_id="O3" value="0.012" spread="0.0228"/>
                    <measurement group_id="O4" value="0.014" spread="0.0224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck At Month 24, n = 315,319,306,316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.0265"/>
                    <measurement group_id="O2" value="0.013" spread="0.0272"/>
                    <measurement group_id="O3" value="0.017" spread="0.0248"/>
                    <measurement group_id="O4" value="0.020" spread="0.0257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Lumbar Spine (L2 - L4) BMD Above or Equal to Baseline at Months 12 and 24</title>
        <description>A participant is a responder if the mean lumber spine (L2 – L4) BMD had remained the same or increased above baseline.</description>
        <time_frame>Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Lumbar Spine (L2 - L4) BMD Above or Equal to Baseline at Months 12 and 24</title>
          <description>A participant is a responder if the mean lumber spine (L2 – L4) BMD had remained the same or increased above baseline.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 12, n = 314,322,306,314</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8"/>
                    <measurement group_id="O2" value="87.6"/>
                    <measurement group_id="O3" value="86.6"/>
                    <measurement group_id="O4" value="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 24, n = 294,294,278,291</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="87.8"/>
                    <measurement group_id="O3" value="87.8"/>
                    <measurement group_id="O4" value="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Months 12 and 24</title>
        <description>A participant is a responder if the mean total hip BMD had remained the same or increased above baseline.</description>
        <time_frame>Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Months 12 and 24</title>
          <description>A participant is a responder if the mean total hip BMD had remained the same or increased above baseline.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 12, n = 315,319,306,306</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8"/>
                    <measurement group_id="O2" value="81.2"/>
                    <measurement group_id="O3" value="86.9"/>
                    <measurement group_id="O4" value="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 24, n = 292,291,277,289</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4"/>
                    <measurement group_id="O2" value="83.2"/>
                    <measurement group_id="O3" value="88.8"/>
                    <measurement group_id="O4" value="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Months 12 and 24</title>
        <description>A participant is a responder if the mean trochanter BMD had remained the same or increased above baseline.</description>
        <time_frame>Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Months 12 and 24</title>
          <description>A participant is a responder if the mean trochanter BMD had remained the same or increased above baseline.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 12, n = 315,319,306,316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="83.1"/>
                    <measurement group_id="O3" value="88.2"/>
                    <measurement group_id="O4" value="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 24, n = 292,291,277,289</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2"/>
                    <measurement group_id="O2" value="86.6"/>
                    <measurement group_id="O3" value="89.9"/>
                    <measurement group_id="O4" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Months 12 and 24</title>
        <description>A participant is a responder if the mean femoral neck BMD had remained the same or increased above baseline.</description>
        <time_frame>Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Months 12 and 24</title>
          <description>A participant is a responder if the mean femoral neck BMD had remained the same or increased above baseline.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 12, n = 315,319,306,316</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1"/>
                    <measurement group_id="O2" value="72.4"/>
                    <measurement group_id="O3" value="69.0"/>
                    <measurement group_id="O4" value="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 24, n = 292,291,277,289</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="71.1"/>
                    <measurement group_id="O3" value="78.7"/>
                    <measurement group_id="O4" value="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24</title>
        <description>A participant is a responder if the mean total hip and mean lumbar spine BMD had remained the same or increased above baseline.</description>
        <time_frame>Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24</title>
          <description>A participant is a responder if the mean total hip and mean lumbar spine BMD had remained the same or increased above baseline.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 12, n = 314,318,304,310</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6"/>
                    <measurement group_id="O2" value="72.3"/>
                    <measurement group_id="O3" value="77.6"/>
                    <measurement group_id="O4" value="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 24, n = 292,291,276,287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="75.3"/>
                    <measurement group_id="O3" value="79.3"/>
                    <measurement group_id="O4" value="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24</title>
        <description>A participant is a responder if the mean trochanter and lumbar spine BMD had remained the same or increased above baseline.</description>
        <time_frame>Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24</title>
          <description>A participant is a responder if the mean trochanter and lumbar spine BMD had remained the same or increased above baseline.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 12, n = 314,318,304,310</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="75.5"/>
                    <measurement group_id="O3" value="78.0"/>
                    <measurement group_id="O4" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 24, n = 292,291,276,287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7"/>
                    <measurement group_id="O2" value="77.3"/>
                    <measurement group_id="O3" value="80.1"/>
                    <measurement group_id="O4" value="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24</title>
        <description>A participant is a responder if the mean femoral neck and lumbar spine BMD had remained the same or increased above baseline.</description>
        <time_frame>Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Months 12 and 24</title>
          <description>A participant is a responder if the mean femoral neck and lumbar spine BMD had remained the same or increased above baseline.</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="304"/>
                <count group_id="O4" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 12, n = 314,318,304,310</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4"/>
                    <measurement group_id="O2" value="64.5"/>
                    <measurement group_id="O3" value="60.9"/>
                    <measurement group_id="O4" value="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 24, n = 292,291,276,287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4"/>
                    <measurement group_id="O2" value="63.9"/>
                    <measurement group_id="O3" value="71.0"/>
                    <measurement group_id="O4" value="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change In Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen [ CTX] ] to Months 3, 6, 12, and 24</title>
        <description>Serum CTX, a biochemical marker of bone resorption, was assessed using the Elecsys S-CTX-I assay (an ElectroChemiLuminescence Immunoassay (ECLIA) Technique).</description>
        <time_frame>From Baseline (Month 0) to Months 3, 6, 12, 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change In Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen [ CTX] ] to Months 3, 6, 12, and 24</title>
          <description>Serum CTX, a biochemical marker of bone resorption, was assessed using the Elecsys S-CTX-I assay (an ElectroChemiLuminescence Immunoassay (ECLIA) Technique).</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="278"/>
                <count group_id="O3" value="276"/>
                <count group_id="O4" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Month 3, n = 269,278,271,276</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.5458" spread="30.8286"/>
                    <measurement group_id="O2" value="-46.4771" spread="26.5096"/>
                    <measurement group_id="O3" value="-50.2368" spread="28.1576"/>
                    <measurement group_id="O4" value="-57.3433" spread="33.9505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 6, n = 270,272,274,278</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5900" spread="34.1672"/>
                    <measurement group_id="O2" value="-53.9838" spread="27.3557"/>
                    <measurement group_id="O3" value="-55.9614" spread="31.2801"/>
                    <measurement group_id="O4" value="-66.4354" spread="25.4762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 12, n = 272,276,276,267</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.8244" spread="29.8250"/>
                    <measurement group_id="O2" value="-57.5363" spread="27.2271"/>
                    <measurement group_id="O3" value="-58.1046" spread="33.5095"/>
                    <measurement group_id="O4" value="-67.0703" spread="41.4563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 24, n = 221,215,211,235</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.2360" spread="37.9032"/>
                    <measurement group_id="O2" value="-51.3040" spread="27.9844"/>
                    <measurement group_id="O3" value="-49.5567" spread="44.9707"/>
                    <measurement group_id="O4" value="61.8822" spread="28.2309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change In Baseline in Serum CTX to Months 12 and 24</title>
        <description>Serum CTX, a biochemical marker of bone resorption, was assessed using the Elecsys S-CTX-I assay (an ElectroChemiLuminescence Immunoassay (ECLIA) Technique).</description>
        <time_frame>From Baseline (Month 0) to Months 12 and 24</time_frame>
        <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change In Baseline in Serum CTX to Months 12 and 24</title>
          <description>Serum CTX, a biochemical marker of bone resorption, was assessed using the Elecsys S-CTX-I assay (an ElectroChemiLuminescence Immunoassay (ECLIA) Technique).</description>
          <population>The PP population consisted of all participants in the ITT population who had no major violations of the protocol. n = number of participants evaluable at particular time of assessment.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
                <count group_id="O4" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12, n = 272, 276, 276, 267</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.323" spread="0.2292"/>
                    <measurement group_id="O2" value="-0.326" spread="0.2212"/>
                    <measurement group_id="O3" value="-0.340" spread="0.2287"/>
                    <measurement group_id="O4" value="-0.377" spread="0.2135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n = 221, 215, 211, 235</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.285" spread="0.2052"/>
                    <measurement group_id="O2" value="-0.298" spread="0.1980"/>
                    <measurement group_id="O3" value="-0.312" spread="0.2398"/>
                    <measurement group_id="O4" value="-0.340" spread="0.2062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Events and Serious Adverse Event</title>
        <description>An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
        <time_frame>Up to Month 24</time_frame>
        <population>The safety population consisted of all participants who were randomized and received at least one dose of the study medication, and who have at least one follow-up data point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Events and Serious Adverse Event</title>
          <description>An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
          <population>The safety population consisted of all participants who were randomized and received at least one dose of the study medication, and who have at least one follow-up data point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="396"/>
                <count group_id="O4" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="313"/>
                    <measurement group_id="O3" value="318"/>
                    <measurement group_id="O4" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Participants With Marked Laboratory Abnormalities</title>
        <description>Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from baseline. The reference range for hemoglobin was 110-200 (gram per liter [g/L]), hematocrit was 0.31-0.56 fraction, white blood cells (WBC) was 3.0-18.0 (10*9/L), serum glutamic-pyruvic transaminase (SGPT/ALT) was 0-110 IU/L, blood urea nitrogen (BUN) was 0.0-14.3 (millimoles per Liter [mmol/L]), Chloride was 95-115 (mmol/L), Potassium was 3.0 – 6.0 (mmol/L), Sodium was 130-150 (mmol/L), Calcium was 2.00-2.90 (mmol/L), Phosphate was 0.75 – 1.60 (mmol/L) and Creatinine was 0- 154 (micromoles/liter [umol/L].</description>
        <time_frame>Up to Month 24</time_frame>
        <population>The safety population consisted of all participants who were randomized and received at least one dose of the study medication, and who have at least one follow-up data point. n = number of participants evaluable at particular time of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibandronate 2.5 mg</title>
            <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 50/50 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O3">
            <title>Ibandronate 100 mg</title>
            <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
          <group group_id="O4">
            <title>Ibandronate 150 mg</title>
            <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Participants With Marked Laboratory Abnormalities</title>
          <description>Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from baseline. The reference range for hemoglobin was 110-200 (gram per liter [g/L]), hematocrit was 0.31-0.56 fraction, white blood cells (WBC) was 3.0-18.0 (10*9/L), serum glutamic-pyruvic transaminase (SGPT/ALT) was 0-110 IU/L, blood urea nitrogen (BUN) was 0.0-14.3 (millimoles per Liter [mmol/L]), Chloride was 95-115 (mmol/L), Potassium was 3.0 – 6.0 (mmol/L), Sodium was 130-150 (mmol/L), Calcium was 2.00-2.90 (mmol/L), Phosphate was 0.75 – 1.60 (mmol/L) and Creatinine was 0- 154 (micromoles/liter [umol/L].</description>
          <population>The safety population consisted of all participants who were randomized and received at least one dose of the study medication, and who have at least one follow-up data point. n = number of participants evaluable at particular time of assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="390"/>
                <count group_id="O3" value="385"/>
                <count group_id="O4" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit Low, n = 389,387,382,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin High, n = 389,389,382,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Low, n = 389,389,382,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC Low, n = 389,389,382,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (SGPT) High, n = 390,390,385,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN High, n = 390,390,385,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine High, n = 390,390,385,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Low, n =3 89,390,385,384</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium Low, n = 389,390,385,383</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium High, n = 389,390,385,384</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Low, n = 389,390,385,384</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium High, n = 390,390,385,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate High, n = 390,390,385,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate Low, n = 390,390,385,385</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>SAEs and non-serious AEs were reported for members of the Safety Population, comprised of participants who were randomized and had at least one dose of study drug, whether withdrawn prematurely or not, and who had at least one follow-up data point.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibandronate 2.5 mg</title>
          <description>Participants received 2.5 mg ibandronate PO daily and an oblong placebo tablet PO monthly Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
        <group group_id="E2">
          <title>Ibandronate 50/50 mg</title>
          <description>Participants received 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
        <group group_id="E3">
          <title>Ibandronate 100 mg</title>
          <description>Participants received 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
        <group group_id="E4">
          <title>Ibandronate 150 mg</title>
          <description>Participants received 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants also received calcium 500 mg /day and vitamin D 400 IU/day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (7.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst of ovary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dacryocystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Ear infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Laryngopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Superinfection lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pain trauma activated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Localised osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Spondylosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Toe deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Gammopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Urethral syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Laryngeal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cyst removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Eventration procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (7.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="182" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="396"/>
              </event>
              <event>
                <sub_title>Localised osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="396"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="396"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor’s intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

